ISSN 1075-2765
13 papers in the library · 78 citations · publishing 0-2026
American Journal of Therapeutics February 20, 2026 Burton J. Tabaac, Kenneth Shinozuka, Anne Weisman et al.
Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric conditions, warranting larger RCTs.
American Journal of Therapeutics November 1, 2024
The first sentence in the Limitations section of the abstract for “Psychedelic Therapy: A Primer for Primary Care Clinicians - N,N-Dimethyltryptamine and Ayahuasca” stated:“There has only been a single published double-blind randomized controlled trial on ayahuasca and 2 on DMT.” The end of this sentence is incorrect. There are no published, double-blind randomized controlled trials on DMT as...
American Journal of Therapeutics March 1, 2024 Kirsten Cherian, Kenneth Shinozuka, Burton J. Tabaac et al. 9 citations
BACKGROUND: Ibogaine is a plant-derived alkaloid that has been used for thousands of years in rites of passage and spiritual ceremonies in West-Central Africa. In the West, it has primarily been used and studied for its anti-addictive properties and more recently for other neuropsychiatric indications, including post-traumatic stress disorder, depression, anxiety, and traumatic brain injury....
American Journal of Therapeutics 2024 Kristine C. Willett, LeDea R. Bond, Amanda M. Morrill et al.
Background: Major depressive disorder (MDD) affects millions of people and is the leading cause of disability worldwide. Patients report decreased quality of life and ability to perform activities of daily living. It is estimated that the current standard of care, which includes pharmacologic therapy with a selective serotonin reuptake inhibitor, is effective in 40%–60%. Additional treatment...
American Journal of Therapeutics Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al. 14 citations
The primary psychoactive drug in magic mushrooms, psilocybin, induces profound alterations in consciousness through the 5-HT2A receptor. This review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin. Despite initial concerns that psilocybin could cause psychosis, contemporary research has demonstrated that psilocybin is...
American Journal of Therapeutics Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al. 12 citations
Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsychiatric conditions, including those that are treatment-resistent. The latter half of the 20th century marked a revolution in the treatment of mental illnesses, exemplified by the introduction of selective serotonin reuptake inhibitors and other...
American Journal of Therapeutics Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas et al. 12 citations
N,N-dimethyltryptamine (DMT) is a naturally occurring serotonergic psychedelic found in natural plants around the globe. As the main psychoactive component in ayahuasca, which also contains monoamine oxidase inhibitors, DMT has been consumed as plant-based brew by indigenous peoples for centuries. Further research is required to delineate the therapeutic utility of DMT. Although previous...
American Journal of Therapeutics Bryce D. Beutler, Kenneth Shinozuka, Burton J. Tabaac et al. 11 citations
Lysergic acid diethylamide (LSD) is a hallucinogenic agent. In the mid-20th century, it was used to augment psychoanalysis and to treat alcohol use disorder. However, LSD was banned in 1970 in part because of concerns that it could bring about or exacerbate mental illness. Its therapeutic potential remains incompletely understood. While uncontrolled recreational use of LSD can, in rare...
American Journal of Therapeutics Viviana D. Evans, Alejandro Arenas, Kenneth Shinozuka et al. 10 citations
Ketamine, an arylcyclohexylamine dissociative anesthetic agent, has evolved into a versatile therapeutic. It has a rapid-onset, well-understood cardiovascular effects and a favorable safety profile in clinical use. Its enantiomeric compound, esketamine, was approved by the Food and Drug Administration in 2019 for both treatment-resistant depression and major depressive disorder with suicidal...
American Journal of Therapeutics Amna M. Aslam, Kenneth Shinozuka, Owen S. Muir et al. 5 citations
Ketamine has emerged as a novel treatment for psychiatric disorders, particularly treatment-resistant depression (TRD). Although intravenous (IV) ketamine is not approved by the Food and Drug Administration (FDA) for TRD, esketamine, an FDA-approved therapeutic, has contributed to the widespread clinical use of off-label IV ketamine across the United States. This scoping review highlights...
American Journal of Therapeutics Owen S. Muir, Kenneth Shinozuka, Bryce D. Beutler et al. 5 citations
The reviews in this special edition have presented a primer on the state of the literature for 7 different psychedelic compounds and their plausible roles in medicine. In a common format underscoring strengths, weakness, opportunities, and threats (SWOT), this article addresses how psychedelic compounds fit into the broader health care landscape for indicated conditions. Historically,...
American Journal of Therapeutics Burton J. Tabaac, Kenneth Shinozuka, Mahdi Fadel et al.
Mescaline (3,4,5-trimethoxyphenethylamine) is a classic serotonergic psychedelic with a history of indigenous ceremonial use. There is renewed scientific interest in mescaline because of the potential psychiatric benefits of psychedelic-assisted therapy. Mescaline primarily exerts its psychoactive effects through serotonin-2A (5-HT 2A ) receptor agonism. There is a lack of controlled clinical...
American Journal of Therapeutics Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas et al.
After becoming notorious for its use as a party drug in the 1980s, 3,4-methylenedioxy-methampetamine (MDMA), also known by its street names "molly" and "ecstasy," has emerged as a powerful treatment for post-traumatic stress disorder (PTSD). There are extensive data about the risk profile of MDMA. However, the literature is significantly biased. Animal models demonstrating neurotoxic or adverse...